WEBINAR: Medicare Drug Price Negotiation - From Selection to Strategy: Navigating IPAY 2028
Access to this On Demand webinar is by request only. Click here to request access.
With CMS now releasing MFPs for IPAY 2027 and preparations already underway for IPAY 2028, the landscape continues to shift. This focused 1-hour webinar brings together advisors from Verpora and Manatt Health — joined for the first time by a US payer perspective — to examine what’s changing and how manufacturers should respond.
Unlike our previous IPAY webinars, which focused on lessons from previous cycles, this session looks ahead — addressing early strategy for selected products, the inclusion of Part B medicines, and the impact of broader political and regulatory developments.
In this session:
How CMS’s approach has evolved between IPAY 2026 and 2027 — and what that signals for IPAY 2028
The new complexity introduced by Part B inclusion in IPAY 2028
Manufacturer strategy: how early preparation shapes outcomes
Most Favored Nation (MFN) pricing pressures and negotiation dynamics
The payer response: formulary strategy, unintended consequences, and future readiness
Thinking ahead to IPAY 2028 or preparing for possible selection?
Use Verpora’s insight to sharpen your early strategy and better understand what’s coming.
Email wanda.lesowiec@verpora.com to start the conversation.
Speakers
Adam Buckler
VP Innovative Contracting
LinkedIn
Omar Ali
Head of Payers, Verpora
LinkedIn
Chris Webber
Head of Negotiation, Verpora
LinkedIn
Webinar Disclaimer: This presentation is for discussion purposes only. No part of this presentation is intended as legal advice. This presentation is based on non-confidential, publicly sourced intelligence. Views expressed by the speakers are personal opinion and should not be attributed to anyone else. No part of this webinar may be reproduced for commercial purposes without the express permission of Verpora and Manatt Health.
